Page 163 - NobleCon20-Book-Project

Syra Health Corp.

SELECTED FINANCIAL ITEMS SYRA

(in millions of USD)
CQ4 '23 CQ1 '24 CQ2 '24 CQ3 '24 LTM
Income Statement Key Items
Total Revenue 1.77 1.75 1.97 2.25 7.74
Gross Profit 0.58 0.18 0.35 0.67 1.78
Gross Margin 33% 10% 18% 30% 23%
EBIT (0.99) (1.44) (1.39) (0.43) (4.25)
EBIT Margin -56% -82% -71% -19% -55%
Net Income to Common Shareholders (1.00) (1.45) (1.39) (0.42) (4.25)
Net Margin -56% -83% -71% -19% -55%

Balance Sheet Key Items
Total Assets 4.92 4.55 3.24 4.43 4.43
Cash & Short Term Investments 3.28 3.24 1.59 2.70 2.70
% of Assets 67% 71% 49% 61% 61%
Current Assets -Total 4.78 4.45 2.83 4.06 4.06
% of Assets 97% 98% 87% 92% 92%
Total Liabilities 0.91 1.10 1.15 1.09 1.09
% of Assets 18% 24% 35% 25% 25%
Current Liabilities - Total 0.91 1.10 0.90 0.88 0.88
% of Assets 18% 24% 28% 20% 20%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 4.01 3.45 2.09 3.33 3.33
% of Assets 82% 76% 65% 75% 75%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (1.76) (0.80) (1.50) (0.41) (4.47)
Net Cash Flow - Investing 0.00 (0.01) (0.01) 0.00 (0.01)
Net Cash Flow - Financing 5.02 0.76 (0.13) 1.52 7.16

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twentieth Annual Small & Microcap Investor Conference